Oligopeptide induction of a secondary cytotoxic T-cell response to Epstein-Barr virus in vitro
- PMID: 1708166
- DOI: 10.1111/j.1365-3083.1991.tb01789.x
Oligopeptide induction of a secondary cytotoxic T-cell response to Epstein-Barr virus in vitro
Abstract
Three Epstein-Barr virus (EBV) nuclear antigen (EBNA)-encoded oligopeptide epitopes have been mapped, each capable of acting as a recognition determinant for class I-restricted lysis by CD8+ cytotoxic T lymphocytes (CTL). This report shows that each peptide, when presented on an appropriate autologous antigen-presenting cell (APC), also stimulates EBV-specific memory T cells present in peripheral blood mononuclear cell (PBMC) populations to develop in vitro into peptide-specific CTL. These CTL specifically lysed autologous EBV-infected lymphoblastoid cell lines (LCL) and peptide-sensitized uninfected targets. Identical viral oligopeptides could therefore function as recognition determinants for both the induction and commission of class I-restricted specific cytotoxicity. A model system is described in which autologous phytohaemagglutinin (PHA) blasts present exogenous peptide during the stimulation phase. The magnitude of the peptide-specific CTL response was dependent on the concentration of peptide added to the APC and specific lysis was inhibited by anti-class I monoclonal antibody (MoAb) but not anti-class II MoAb. Cultures depleted of CD8+ T cells by cell separation with immunomagnetic beads prior to stimulation invariably failed to generate a peptide-specific CTL response. However, the effect of CD4 depletion on CTL activity was equivocal and indicated that a need for CD4+ T cells as accessory helper cells may depend on the efficiency of the APC to elaborate their own help. This model has advantages in the analysis of events involved in the development of CTL activity in vitro.
Similar articles
-
Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component.Cell Immunol. 1991 Feb;132(2):295-307. doi: 10.1016/0008-8749(91)90029-b. Cell Immunol. 1991. PMID: 1846323
-
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.J Exp Med. 1995 Jun 1;181(6):2221-8. doi: 10.1084/jem.181.6.2221. J Exp Med. 1995. PMID: 7539044 Free PMC article.
-
Cytotoxic T lymphocyte discrimination between type A Epstein-Barr virus transformants is mapped to an immunodominant epitope in EBNA 3.J Gen Virol. 1991 Feb;72 ( Pt 2):405-9. doi: 10.1099/0022-1317-72-2-405. J Gen Virol. 1991. PMID: 1704413
-
T cell recognition of Epstein-Barr virus associated lymphomas.Cancer Surv. 1992;13:53-80. Cancer Surv. 1992. PMID: 1330300 Review.
-
Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis.Springer Semin Immunopathol. 1991;13(2):147-56. doi: 10.1007/BF00201465. Springer Semin Immunopathol. 1991. PMID: 1724100 Review. No abstract available.
Cited by
-
Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9478-82. doi: 10.1073/pnas.88.21.9478. Proc Natl Acad Sci U S A. 1991. PMID: 1719531 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials